BX-001N Experimental group 2

Phase 2

BX-001N Experimental group 2 is one of 13 therapeutic programs targeting Ischemia Reperfusion Injury. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Ischemia Reperfusion InjuryRecruiting

Ischemia Reperfusion InjuryPhase 2

Recruiting

Competition

Competitive Landscape

16 competitors in Ischemia Reperfusion Injury

#DrugCompanyPhaseTrials

Farxiga

Levitra

Neoral

Remodulin

Colcrys

Inomax

Cardizem

BBausch Health Americas, Inc.

Approved

—8

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—9

Nitrostat

VViatris Specialty LLC

Glucophage

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Ischemia Reperfusion Injury

NCT07164833

Clinical

Trials by Indication[1]

Ischemia Reperfusion Injury1 trial

Randomized, Single-blind, Multi-center, Placebo-controlled, Phase 2a Clinical Trial of BX-001N to Prevent From Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE)

Recruiting·BBilix Co.,Ltd.·Phase 2·NCT07164833·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BX-001N Experimental group 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for BX-001N Experimental group 2. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Bilix Co.,Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: BBilix Co.,Ltd.

BX-001N Experimental group 2

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Ischemia Reperfusion Injury1 trial

References

Drug Info

Quick Facts

Related News